The largest study of its kind to date shows that minimally invasive radioembolization may slow metastatic disease progression in liver when no other treatment options remain, according to research being presented at the Society of Interventional Radiology’s 39th Annual Scientific Meeting (22–27 March, San Diego, USA).
The outcomes from our study on the efficacy and safety of percutaneous cryoablation, published recently in CardioVascular and Interventional Radiology (CVIR), are the result of the most rigorous investigation on the subject to-date. These exceptional numbers, however, are a double-edged sword. On one hand, they approach those of the gold standard, on the other, we must prove they are widely reproducible, writes Christos Georgiades
Investigators from the MORE (Metastatic colorectal cancer liver metastases outcomes after radioembolization) study have released new findings at the American Society of Clinical Oncology’s 2014 Gastrointestinal Cancers Symposium confirming that standard laboratory tests are a valuable tool for predicting patient outcomes prior to Selective Internal Radiation Therapy (SIRT).
Cryoablation kills tumours and provides pain relief to patients whose cancer has spread to the bone and soft tissue, suggests research being presented at the 6th annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET).
A prospective single-arm, five-year study has found that CT-guided percutaneous cryoablation for renal cell carcinoma offers very high efficacy, approaching that of the gold standard, surgery. Cryoablation also has a more favourable safety profile.
Future Medicine Ltd has announced the launch of a new journal, Hepatic Oncology. This new title focuses specifically on the specialism of hepatic cancer, including both primary and secondary malignancies.
An important opportunity has opened up for interventional oncologists as WCIO leaders take the helm of the E1208 trial. Michael C Soulen writes that the change in the trial leadership from medical oncology to interventional oncology represents a challenge because it rests on the question: can interventional oncologists run a successful cooperative group trial of image-guided therapy?
Guerbet has announced that it has been granted Orphan Drug Designation from the US Food and Drug Administration Office of Orphan Products Development (OOPD) for Lipiodol (ethiodised oil) injection for management of patients with known hepatocellular carcinoma.
The NHS revision of Clinical Policy Commissioning Statement on SIRT will allow patients in England with metastatic colorectal cancer and intrahepatic cholangiocarcinoma who may benefit from the therapy to get treatment in specialist NHS centres.
Angiovac cannula and cardiopulmonary bypass circuit, Bioflo peripherally inserted central catheters, Nanoknife system, Nevertouch direct fibre and Acculis microwave system illustrate strength of company’s portfolio.
Thomas Vogl, Institute of Diagnostic and Interventional Radiology, Goethe University, Frankfurt, spoke at ECIO (19–22 June, Budapest Hungary) about novel lung ablative techniques and the evidence for combination ablative therapies.
The presentation will include the most recent overall survival data. Recent HEAT study post-hoc analysis, strongly suggest positive progression-free survival and overall survival in ThermoDox treated patients when heating cycles from the radiofrequency ablation procedure were optimised.
For the two-thirds of lung cancer patients with locally advanced or metastatic disease, tumour size is not used currently to predict overall survival times. A new study, however, led by UT Southwestern Medical Center researchers has shown that even in advanced stages, total tumour size can have a major impact on survival.
Results of an analysis by members of the multicentre European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY), published online in late May in the Journal of Hepatology, may have important implications for older patients with inoperable primary liver cancer.
BTG announced on 30 July that the National Institute for Health and Clinical Excellence (NICE) has issued guidance recommending the use of selective internal radiation therapy (SIRT), which includes TheraSphere, for patients with liver cancer across the NHS.
In the IN.PACT SFA trial, the device demonstrated the lowest clinically-driven target lesion revascularisation rate (2.4%) ever reported for an interventional treatment of peripheral arterial disease ...